Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GNRHR | P30968 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674720 | 0.86 | TLR8 (0.49) | HSP90AA1HSP90AB1HPGDALDH1A1LMNA | |
| SCHEMBL676064 | 0.83 | RIPK1 (0.41) | HPGDALDH1A1LMNATLR9TLR8 | |
| SCHEMBL676178 | 0.81 | GRM5 (0.46) | HSP90AA1HSP90AB1HPGDALDH1A1LMNA | |
| SCHEMBL676197 | 0.80 | KIF11 (0.48) | HSP90AA1HPGDALDH1A1LMNATSHR | |
| SCHEMBL675341 | 0.79 | TLR9 (0.50) | HSP90AA1HSP90AB1HPGDALDH1A1LMNA | |
| SCHEMBL676048 | 0.79 | GSK3B (0.41) | HPGDALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL675022 | 0.78 | KIF11 (0.41) | HPGDALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL3664810 | 0.77 | MEN1 (0.33) | HPGDALDH1A1LMNATLR9TLR8 | |
| SCHEMBL678686 | 0.77 | TERT (0.35) | HPGDALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL674652 | 0.77 | CYP1A2 (0.43) | HPGDALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | HSP90AA1 3653/4885HSP90AB1 2869/4885HPGD 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.